Eeric Truumees, M.D., First Vice President of NASS' Board of Directors, is optimistic that the online virtual annual meeting event in October will allow attendees to benefit from broader input in smaller doses.
To measure and improve patient care, NASS has launched a diagnosis-based clinical data registry to track outcomes. The web-based platform will allow healthcare providers to collect and analyze their spine care data and compare it to the de-identified data in the entire registry.
Premia Spine secured FDA approval for a pivotal IDE study of TOPS™, a posterior arthroplasty device for the treatment of spondylolisthesis and spinal stenosis. The study seeks to establish the superiority of TOPS vs. traditional lumbar spinal fusion.
Ferring Pharmaceuticals acquired exclusive development and commercialization rights to Seikagaku's SI-6603 injectable condoliase, a potential treatment for lumbar disc herniation, for up to US $95.0MM in upfront cash plus milestone payments.
Study results from 5-year follow-up demonstrate the long-term, sustained therapeutic effect of Paradigm Spine's coflex® Interlaminar Stabilization® vs. fusion in the treatment of lumbar spinal stenosis.